blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3725802

EP3725802 - ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.09.2020
Database last updated on 13.07.2024
FormerThe international publication has been made
Status updated on  28.05.2019
Most recent event   Tooltip02.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
ABL Bio Inc.
2F 16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
[2020/43]
Inventor(s)01 / LEE, Sang Hoon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
02 / YOU, Weonkyoo
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
03 / AHN, Jinhyung
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
04 / AN, Sungwon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
05 / JUNG, Jinwon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
06 / LEE, Bora
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
07 / KIM, Dongin
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
08 / SUNG, Byungje
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
09 / SON, Yonggyu
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
10 / KIM, Yeunju
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
11 / EOM, Jaehyun
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
12 / AHN, Seawon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
13 / PAK, Youngdon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
14 / YEOM, Donghoon
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
15 / SONG, Daehae
16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si Gyeonggi-do 13488 / KR
 [2020/43]
Representative(s)Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[N/P]
Former [2020/43]Hoppe, Georg Johannes
Darani Anwaltskanzlei
Beuckestrasse 20
14163 Berlin / DE
Application number, filing date18879299.816.11.2018
[2020/43]
WO2018KR14123
Priority number, dateUS201762588018P17.11.2017         Original published format: US 201762588018 P
US201862687848P21.06.2018         Original published format: US 201862687848 P
[2020/43]
Filing languageKO
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2019098763
Date:23.05.2019
Language:KO
[2019/21]
Type: A2 Application without search report 
No.:EP3725802
Date:21.10.2020
Language:EN
[2020/43]
Search report(s)International search report - published on:KR11.07.2019
(Supplementary) European search report - dispatched on:EP08.07.2021
ClassificationIPC:C07K16/18, G01N33/68, A61P25/16, A61P25/28
[2020/43]
CPC:
A61P25/16 (EP,KR); C07K16/18 (EP,KR,US); A61P25/28 (EP,KR,US);
G01N33/6896 (EP,KR,US); A61K2039/505 (EP); C07K2317/24 (EP,KR);
C07K2317/34 (EP); C07K2317/565 (EP,KR,US); C07K2317/567 (KR,US);
C07K2317/76 (EP,KR); C07K2317/92 (EP,KR); G01N2333/46 (KR);
G01N2800/2821 (EP,US); G01N2800/2835 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/43]
TitleGerman:ANTIKÖRPER GEGEN ALPHA-SYNUKLEIN UND VERWENDUNGEN DAVON[2020/43]
English:ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF[2020/43]
French:ANTICORPS ANTI-SYNUCLÉINE ET LEURS UTILISATIONS[2020/43]
Entry into regional phase11.05.2020Translation filed 
11.05.2020National basic fee paid 
11.05.2020Search fee paid 
11.05.2020Designation fee(s) paid 
11.05.2020Examination fee paid 
Examination procedure11.05.2020Examination requested  [2020/43]
31.01.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
23.11.2020Renewal fee patent year 03
15.11.2021Renewal fee patent year 04
13.10.2022Renewal fee patent year 05
29.09.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XPA]WO2018128454  (ABL BIO INC [KR]) [XP] 1-3,9-14 * the whole document *[A] 4-8
International search[A]WO2011104696  (BIOARCTIC NEUROSCIENCE AB [SE], et al) [A] 1-21, 21(1), 26-31 * See abstract, claims 1-3, 6, 7, 10, 14, paragraph [0024] and sequence identifier nos. 24, 46, 49, 56, 58. *;
 [A]WO2011107544  (RENTSCHLER HOLDING GMBH & CO KG DR [DE], et al) [A] 1-21, 21(1), 26-31 * See abstract, claims 1, 3, 40, 41, 43 and sequence identifier no. 31. *;
 [A]KR20140053974  (BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH [CH], et al) [A] 1-21, 21(1), 26-31 * See abstract, claims 1, 4, 46, 47, 53, 55, 61, 70, 74, 76 and paragraph [0003]. *;
 [A]KR20160010402  (UNIV UNITED ARAB EMIRATES [AE]) [A] 1-21, 21(1), 26-31 * See abstract and claims 1-3, 17, 19. *;
 [A]WO2017009312  (H LUNDBECK AS [DK]) [A] 1-21, 21(1), 26-31* See abstract and claims 1-5, 27. # Claim 21 is used twice, so that the second claim 21 has been written as claim 2.(1). *
by applicantUS5260203
 US5585089
 US5693762
    - SONGSIVILAILACHMANN, Clin. Exp. Immunol., (19900000), vol. 79, pages 315 - 321
    - KOSTELNY et al., J. Immunol., (19920000), vol. 148, pages 1547 - 1553
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 878 - 883
    - CHOTHIALESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 27
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - KIM et al., Alzheimer's Research & Therapy, (20140000), vol. 6, page 73
    - MCKEITH et al., Neurology, (19960000), vol. 47, pages 1113 - 24
    - AHN, Mol. Cells, (20040000), vol. 18, no. 2, pages 237 - 241
    - BAE et al., J. Neurosci, (20120000), vol. 32, page 13454
    - BAE et al., J Neurosci., (20120926), vol. 32, no. 39, pages 13454 - 13469
    - LEE HJ et al., J. Neurosci., (20040000), vol. 24, pages 1888 - 1896
    - CHEMICAL ABSTRACTS, Database accession no. 107761-42-2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.